Baird Medical Proudly Invited to Showcase Microwave Ablation Technology at the ACS Clinical Congress
Rhea-AI Summary
Baird Medical (NASDAQ: BDMD) participated in the 2024 American College of Surgeons Clinical Congress in San Francisco, showcasing its microwave ablation (MWA) technology to over 10,000 attendees, including 7,000 surgeons. At Booth 1061, the company demonstrated MWA applications for thyroid nodules, breast disease, liver cancer, and uterine fibroids. The technology, already adopted by institutions like Columbia University and Weill Cornell, attracted significant interest through hands-on simulations. Baird participated in panel discussions on ablative therapies and engaged with endocrine surgery leaders, reinforcing its commitment to market expansion.
Positive
- Technology adopted by prestigious institutions (Columbia University, Weill Cornell, Tulane University)
- Strong presence at major industry event with 10,000+ attendees
- Diverse application potential across multiple medical conditions
Negative
- None.
News Market Reaction – BDMD
In the trading session that priced this news, BDMD gained 3.27%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The ACS, established in 1913, is the world's largest and most influential organization for surgeons, boasting more than 90,000 members across 144 countries. The annual Clinical Congress serves as a key platform for discussing surgical advancements, exploring new technologies, and fostering collaboration within the medical community.
On October 20, Baird Medical showcased its cutting-edge microwave ablation devices at Booth 1061, highlighting their applications in treating thyroid nodules, breast disease, liver cancer, and uterine fibroids. Baird's innovative MWA technology, which has been adopted by top institutions such as
The live demonstrations of Baird's MWA technology were a standout feature of the exhibition. Surgeons from the
Throughout the congress, Baird Medical actively engaged with key thought leaders and participated in a range of panel discussions, including sessions on "Emerging Ablative Therapies for Breast Cancer" and "Endocrine Surgery." These panels provided valuable insights into the future of ablation techniques and reinforced the growing interest in minimally invasive solutions for various conditions.
A major highlight of the event was reuniting with prominent leaders in the field of endocrine surgery and interventional endocrinology from top institutions. These collaborative discussions further strengthened Baird's mission to enhance patient care through innovative technology and fostered ongoing relationships with experts who have been instrumental in advancing the use of MWA in clinical practice.
As the ACS Clinical Congress ended, Baird Medical reaffirmed its commitment to expanding its presence in the
About the ACS Clinical Congress
The American College of Surgeons (ACS) Clinical Congress is one of the world's largest gatherings of surgeons, dedicated to sharing advancements in surgical techniques and improving patient care. The congress brings together thousands of professionals from across the globe to exchange knowledge and foster collaborations that advance clinical practices.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-proudly-invited-to-showcase-microwave-ablation-technology-at-the-acs-clinical-congress-302285609.html
SOURCE Baird Medical LLC